Patients should maintain adequate hydration, and those with pre-existing renal impairment should be monitored carefully
Here, sequences from 77 species that have intact coding sequences from all three receptors ( Gcgr , Glp1r , and Glp2r ) and Gcg were used
Similar to GLP-1(7-37), exenatide also acts as an agonist for GLP-1(7-37), but shows resistance to DPP-4 degradation and has a lower renal clearance rate in human, making exenatide the first successfully developed GLP-1 drug [6]
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
It is not intended for: Human or animal consumption Injection or self-administration Treatment, cure, or mitigation of any disease Clinical or therapeutic use Cosmetic or wellness use Use must comply with all applicable institutional, provincial, and federal regulations governing research chemicals and biologically active peptides
Furthermore, butyrate-induced GLP-1 secretion is attenuated in FFAR3 knockout mice (51)
